Global Molecular Cytogenetic Market – Industry Trends and Forecast to 2030

Molecular Cytogenetic Market Analysis and Size

According to the WHO, Cancer is one of the leading causes of death, accounting for 11.5 million deaths worldwide in 2030. Lung cancer is a leading cause of death in men and women alike. Currently, there are numerous commercially available kits for cancer diagnosis, with Abbott Molecular's UroVysion bladder cancer kit being the only one available for early detection of bladder cancer. Similarly, commercially available detection kits include PathVysion for breast cancer, Vysis CLL FISH probe kit for haematological disorders, and others.

Data Bridge Market Research analyses that the molecular cytogenetic market which was USD 2.76 billion in 2022, is expected to reach USD 5.80 billion by 2030, at a CAGR of 9.7% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Molecular Cytogenetic Market Scope and Segmentation  

Market Definition

Molecular cytogenetic combines molecular biology and cytogenetics. Cytogenetics is the study of chromosomes, and molecular cytogenetics is the analysis of genetic variations or alterations using in-situ hybridization techniques. Molecular cytogenetics has critical applications in biology and medicine. Molecular cytogenetics is the study of the structural and functional organization of the chromosomes and their nucleus, genomic variations, expression and evolution, and chromosomal abnormalities, particularly in medicinal and cancer genetics. Techniques such as fluorescence in situ hybridization (FISH) are used in molecular cytogenetics to visualize the entire genome or specific regions of the genome.

Global Molecular Cytogenetic Market Dynamics

Drivers

• Increase in R&D Activities

The large number of research centres in China and India and R&D centres in Japan will increase demand for high-quality molecular cytogenetics. Japan is the leading contributor to the global molecular cytogenetics market, owing to long-standing collaborations between manufacturers and research institutions. Furthermore, personalized medicine's role in treating genetic or other disorders is gaining traction in developed countries, which is expected to boost the market during the forecast period.

• Increasing prevalence of cancer 

Cancer diagnostics primarily drives molecular cytogenetics, and it provides techniques for imaging in genetics, epigenetics, and cytology, as well as the ability to detect chromosomal changes. The rising prevalence of cancer and the resulting need for accurate diagnosis are expected to drive the global molecular cytogenetic market between 2023 and 2030.

Opportunities

• Technically advance healthcare sector

The rising government and private healthcare spending, and improved healthcare infrastructure in this region all contribute to the growth of the molecular cytogenetic market. For instance, a woman in the United States has a 13% chance of developing breast cancer in her lifetime. In 2018, an estimated 234,030 new cases of lung cancer were discovered, and 541,000 Americans have been diagnosed with the disease at some point in their lives. These findings demonstrate the enormous potential for growth and expansion in the molecular cytogenetic market.

Restraints/Challenges

• Lack of Skilled professional

Some factors, such as technical limitations and complexities associated with the equipment, are expected to impede the growth of the molecular cytogenetic market during the forecast period. However, the high cost of cytogenetic instruments and a lack of awareness about advanced technological methodologies, particularly in low and middle-income countries, are expected to hamper market growth during the forecast period.

This molecular cytogenetic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the molecular cytogenetic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Molecular Cytogenetic Market

COVID-19 is expected to have a significant impact on the market. Around the world, there have been several changes in consumer demand and behaviour, purchasing habits, and significant government initiatives. The COVID-19 has altered the population's nutrition, substance use and health-related behaviours. Furthermore, as COVID-19 spreads around the world, hospitalization rates are dropping dramatically. Several reports indicated that many hospitals were operating at less than 50% capacity in order to reduce noncritical medical services and elective surgeries. As a result, COVID-19 is expected to have a large impact on the molecular cytogenetic market.

Recent Developments

• In August 2022, Agilent Technologies Inc. announced the acquisition of Polymer Standards Service GmbH (PSS), a provider of polymer characterization solutions. PSS specializes in hardware and software solutions for defining molecular structure makeup and creation. The company offers complete solutions for gel permeation chromatography (GPC) and size exclusion chromatography (SEC), which are used to determine the molecular weight and size distribution of macromolecules in applications.

Global Molecular Cytogenetic Market Scope

The molecular cytogenetic market is segmented on the basis of technique, product, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technique

• Fluorescence In Situ Hybridization
•  Comparative Genomic Hybridization
• Array-based comparative genomic hybridization
• Standard comparative genomic hybridization
•  In situ Hybridization
•  Karyotyping
• Spectral karyotyping
• Virtual karyotyping
• Banding Techniques
• G banding
• Q banding
•  R banding
•  C banding
• T banding

 Product

• Instruments
•  Kits and Reagents
• Testing kits
• probes
• Fluorescent affinity reagents
• Others
•  Software and Services
•  Consumables/Accessories

Application

• Oncology
•  Genetic Disorders
• Personalized Medicines
• Others

 End User

• Pharmaceuticals and Biotechnology Companies
• Clinical and Diagnostic Laboratories
• Academic Institutes

Molecular Cytogenetic Market Regional Analysis/Insights

The molecular cytogenetic market is analyzed and market size insights and trends are provided by country, technique, product, application and end user as referenced above.

The countries covered in the molecular cytogenetic market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the molecular cytogenetic market due to the presence of an effective regulatory framework for the regulation of genetic tests along with the strong presence of major entities in this particular region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the advancements in human genetics and disease management, as well as the unrelenting GDP growth of emerging countries such as China and India, are likely to increase consumer purchasing power in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Molecular Cytogenetic Market Share Analysis

The molecular cytogenetic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to molecular cytogenetic market.

Some of the major players operating in the molecular cytogenetic market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• Agilent Technologies, Inc. (U.S.)
• PerkinElmer Inc. (U.S.)
• Illumina, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Oxford Gene Technology IP Limited (U.K.)
• Applied Spectral Imaging, Inc. (U.S.)
• Sartorius AG (Germany)
• CytoTest Inc. (U.S.)
• Cytognomix, Inc. (Canada)
• Bionano Genomics (U.S.)
• Precipio (U.S.)
• Leica Biosystems Nussloch GmbH (Germany)

Research Methodology: Global Molecular Cytogenetic Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

SKU-57193